Sunday, February 15, 2026
ISSN 2765-8767
  • Home
  • Courses
  • About Us
  • Contact us
  • Support Us
  • Home
  • Courses
  • About Us
  • Contact us
  • Support Us

Timing social distancing to avert unmanageable hospital surges

How can we best mitigate future pandemic waves while limiting collateral economic damage? As COVID-19 social distancing measures are relaxed across the United States, temporary shelter-in-place orders triggered by monitoring local hospital admissions can minimize the number of days of disruption while preventing overwhelming healthcare surges. We develop a mathematical optimization model on top of an SEIR-style simulation model with age group, risk group, and temporal fidelity. This work has been in response to independent requests from the city of Austin, the state of Texas, the Centers for Disease Control and Prevention, and the White House Coronavirus Task Force to inform strategies for modulating social distancing policies.

Source: National Academy of Sciences

Daily Remedy

Daily Remedy

Dr. Jay K Joshi serves as the editor-in-chief of Daily Remedy. He is a serial entrepreneur and sought after thought-leader for matters related to healthcare innovation and medical jurisprudence. He has published articles on a variety of healthcare topics in both peer-reviewed journals and trade publications. His legal writings include amicus curiae briefs prepared for prominent federal healthcare cases.

Videos

2027 Medicare Advantage & Part D Advance Notice

BIIB080 in Mild Alzheimer’s Disease: What a Phase 1b Exploratory Clinical Analysis Can—and Cannot—Tell Us

BIIB080 in Mild Alzheimer’s Disease: What a Phase 1b Exploratory Clinical Analysis Can—and Cannot—Tell Us

Can lowering tau biology translate into a clinically meaningful slowing of decline in people with early symptomatic Alzheimer’s disease? That is the practical question behind BIIB080, an intrathecal antisense therapy designed to reduce production of tau protein by targeting the tau gene transcript. In a phase 1b program originally designed for safety and dosing, investigators later examined cognitive, functional, and global outcomes as exploratory endpoints. The clinical question matters because current disease-modifying options primarily target amyloid, while tau pathology tracks...

Read more

Join Our Newsletter!